EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Modifying Epigenetic Landscapes to Restore Immune Therapeutic Responses in Triple Negative Breast Cancer

Nabeelah Almalki, Mercedes Vázquez-Cantú, Riba Thomas, Tinyiko Modikoane iD, Mansour Alsaleem iD, Jenny Persson iD, Emad Rakha, Nigel P Mongan iD, Cinzia Allegrucci iD

Cancers · 12.04.2026 · 18 (8) · 1221

DOI: 10.3390/cancers18081221 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.04.2026. Verfasst von Nabeelah Almalki und 8 weiteren Autor:innen. Beteiligte Einrichtung: SVMS and Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer defined by the absence of estrogen and progesterone receptors, as well as the lack of human epidermal growth factor 2 receptor overexpression. TNBC is associated with early onset, high metastatic potential, therapeutic resistance, and poor clinical outcomes exacerbated by the limited availability of effective targeted therapies. Advances in multi-omics profiling have further stratified TNBC into distinct molecular subtypes, each exhibiting unique genomic, epigenomic, and immune-related features that influence therapeutic responsiveness. This review explores the interplay between TNBC molecular heterogeneity, immune evasion mechanisms, and epigenetic regulation. TNBC demonstrates variable immunogenicity, with tumor-infiltrating lymphocytes serving as important prognostic and predictive biomarkers. However, immune escape commonly occurs through tumor microenvironment remodeling, T-cell exhaustion, cancer stem cell enrichment, and immune checkpoint pathways activation. Although immune checkpoint inhibitors have improved outcomes in selected patients, particularly in combination with chemotherapy, primary and acquired therapeutic resistance remain a significant challenge. Emerging evidence highlights the central role of epigenetic mechanisms in regulating immune-related gene expression and shaping the tumor immune microenvironment. Epigenetic silencing of antigen presentation machinery, interferon signaling pathways, and chemokine expression contributes to immune evasion and immunotherapy resistance. Importantly, pharmacological modulation of epigenetic regulators can restore immune recognition and induce “viral mimicry” through reactivation of endogenous retroelements, thereby enhancing antitumor immunity. Collectively, this review underscores the therapeutic potential of integrating epigenetic therapies with immunotherapy and chemotherapy to overcome immune resistance in TNBC. A deeper understanding of epigenetic-immune interactions may facilitate the development of more precise and effective treatment strategies tailored to TNBC molecular subtypes.

Schlagwörter

Stichwörter der Autor:innen

epigenetic therapyepigeneticsimmune evasionimmunotherapytransposonstriple negative breast cancertumor microenvironmentviral mimicry

Autor:innen und Institutionen

  • SVMS and Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqraa 11961, Saudi Arabia.
  • Unit of Scientific Research, Applied College, Qassim University, Buraydah 52571, Saudi Arabia.
  • Department of Molecular Biology, Umea University, 901 87 Umea, Sweden.
  • School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK.
  • Nottingham University NHS Trust, Nottingham NG7 2UH, UK.

ORCID-Profile: Tinyiko Modikoane, Mansour Alsaleem, Jenny Persson, Nigel P Mongan, Cinzia Allegrucci

Förderung

  • Biotechnology and Biological Sciences Research Council

Zitieren

APA

Almalki, N., Vázquez-Cantú, M., Thomas, R., Modikoane, T., Alsaleem, M., Persson, J., Rakha, E., Mongan, N. P., & Allegrucci, C. (2026). Modifying Epigenetic Landscapes to Restore Immune Therapeutic Responses in Triple Negative Breast Cancer. Cancers, 18(8), 1221. https://doi.org/10.3390/cancers18081221

Vancouver

Almalki N, Vázquez-Cantú M, Thomas R, Modikoane T, Alsaleem M, Persson J, et al. Modifying Epigenetic Landscapes to Restore Immune Therapeutic Responses in Triple Negative Breast Cancer. Cancers. 2026;18(8):1221. doi:10.3390/cancers18081221

BibTeX
@article{Almalki2026,
  author = {Almalki, Nabeelah and Vázquez-Cantú, Mercedes and Thomas, Riba and Modikoane, Tinyiko and Alsaleem, Mansour and Persson, Jenny and Rakha, Emad and Mongan, Nigel P and Allegrucci, Cinzia},
  title = {Modifying Epigenetic Landscapes to Restore Immune Therapeutic Responses in Triple Negative Breast Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1221},
  doi = {10.3390/cancers18081221}
}
Kostenlos starten →